David Sourdive
Founder at CELLECTIS S.A.
Net worth: 3 M $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Xavier Lazarus | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 21 years |
André Choulika | M | 59 | 25 years | |
Stephan Reynier | M | 55 |
Ectycell SASU
Ectycell SASU BiotechnologyHealth Technology Ectycell SASU produces and sales stem cells. It offers pluripotent stem cells that can be used to develop drugs and model diseases. The company was founded in September 2009 and is headquartered in Romainville, France. | 13 years |
Pierre Monsan | M | 75 |
Cell-Easy SAS
Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France. | 5 years |
Jean-Guillaume Lafay | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | - |
Benjamin Hadida | M | - |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | - |
Samantha Jérusalmy | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 16 years |
Donald Bergstrom | M | 52 | 2 years | |
Marie-Bleuenn Terrier | F | 42 | 16 years | |
Pierre Dessein | M | - |
Bilhi Genetics SAS
Bilhi Genetics SAS Pharmaceuticals: OtherHealth Technology Bilhi Genetics SAS specializes in the development of predictive medicines. It offers products for hepatic fibrosis and skin scars. The company was founded by David Sourdive and Pierre Dessein in June 2012 and is headquartered in Marseille, France. | - |
Rainer Boehm | M | 63 | 7 years | |
Harry Sokol | M | - |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | 8 years |
Axel-Sven Malkomes | M | 57 | 2 years | |
Warren Viricel | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | 6 years |
Armelle de Tinguy | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 9 years |
Florian Denis | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 5 years |
Alexis Frentz | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 7 years |
Christophe Henri Primault | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 7 years |
Mark Frattini | M | 58 | 4 years | |
Pierre Bastid | M | 69 | 13 years | |
Philippe Gire | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 22 years |
Laurent Arthaud | M | 61 | 13 years | |
Patrick Gervais | M | - |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | 8 years |
Guillaume Costecalde | M | - |
Cell-Easy SAS
Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France. | - |
Jean-Pierre Garnier | M | 75 | 4 years | |
Sofia Dahoune | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 6 years |
Haya Hanna | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 5 years |
Steve Doares | M | - | 4 years | |
Khalil El Jahiri | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | - |
Gabriel Levy | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 4 years |
Sebastien Ribault | M | - |
Cell-Easy SAS
Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France. | 1 years |
Valérie Attuil | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | - |
Arthur Stril | M | 35 | 6 years | |
Pascalyne Wilson | M | - | - | |
Kyung Nam-Wortman | F | 54 | 4 years | |
Delphine Villuendas | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 3 years |
Philippe Langella | M | - |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | - |
Laurent Kott | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 4 years |
Sacha Loiseau | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 5 years |
Franck Lescure | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 6 years |
Emmanuel Perez-Duarte | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 6 years |
Graziano Seghezzi | M | 55 |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | - |
Frederic Hammel | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 5 years |
Pauline Roux | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 10 years |
Philippe Duchateau | M | 61 | 23 years | |
Amelie Juge | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 5 years |
Anne-Sophie Carrese | F | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 7 years |
Valérie Calenda | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | - |
Cédric Favier | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 6 years |
Michael Chekroun | M | - |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | 8 years |
Bervin Bouani | M | - |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | 3 years |
Marc Rougier | M | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | 8 years |
Cécile Chartier | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mathieu Simon | M | 68 |
Ectycell SASU
Ectycell SASU BiotechnologyHealth Technology Ectycell SASU produces and sales stem cells. It offers pluripotent stem cells that can be used to develop drugs and model diseases. The company was founded in September 2009 and is headquartered in Romainville, France. | 6 years |
Simon Harnest | M | 37 | 6 years | |
Marc Le Bozec | M | - | 7 years | |
Jean-Marie Messier | M | 68 | - | |
Thierry Moulin | M | - | - | |
Jean-Charles Epinat | M | - | - | |
Elsy Boglioli Hofman | F | 42 | 2 years | |
Herve Hoppenot | M | 64 | 6 years | |
Annick Schwebig | M | 73 | 12 years | |
Alain Godard | M | 78 | - | |
Delphine Jay | F | - | - | |
Léopold Bertea | M | 60 | - | |
Stephane Depil | M | 50 | 2 years | |
Julia Berretta | M | 43 | - | |
Eric Dutang | M | 50 | - | |
Loan Hoang-Sayag | M | 57 | 1 years | |
Francisco J. Esteva | M | 60 | - | |
Carrie Brownstein | M | 54 | 2 years | |
Bing C. Wang | M | 47 | 2 years | |
Luc Mathis | M | - | 4 years | |
Stefan J. Scherer | M | - | 1 years | |
Dirk Pollet | M | - | 3 years | |
Frédéric Cédrone | M | - | - | |
Philippe Valachs | M | 65 | - | |
Aymeric Duclert | M | - | - | |
Sylvie Delassus | M | - | - | |
William Monteith | M | 65 | 2 years | |
Alain Munoz | M | 75 | - | |
Pierre Schwich | M | - | - | |
Isabelle Pelletier-Bressac | F | - | - | |
Frédéric Pâques | M | - | 11 years | |
Margaret Gandolfo | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
France | 85 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Sourdive
- Personal Network